What is the address of APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE?

The registered office of APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE is located at Ganzemansberg 18, 3020 Herent.

Is APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE still active?

Yes. According to the CBE (31 October 2026) APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE is active, legal situation “Normale toestand”, started on 6 July 1995.

Is APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE registered on Peppol?

No, APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE is currently not registered on the Peppol network.

Who are the directors of APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE?

According to the 2025 annual accounts, the directors of APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE are: Christiaan Julien Vanhentenrijk.

Is APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 6 July 1995; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

What is the revenue of APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE?

As a small company, APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 353,909.

APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE

Q: What is the enterprise number of APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE?

The enterprise number of APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE is BE0455664923.

Q: When was APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE founded?

APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE was founded on 6 July 1995.

Q: How much profit did APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE make in 2025?

APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE posted a profit after taxes of € 243,328 in financial year 2025.

Dossier APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE, printed on 1 November 2026 from databakkes.be/en/0455664923/apotheker-chris-vanhentenrijk-klinische-biologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE from Herent, company number BE0455664923, closed financial year 2025 with a result of € 243,328 after tax. For that financial year APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE recorded a gross margin of € 353,909 and equity of € 967,093. Compared with financial year 2024, the result moved from € 169,454 to € 243,328. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on January 30, 2026.

What it is worth Growing

€ 967,093

▲ 34% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 243,328

▲ 44% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 347,139

▲ € 275,180 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 954,701.

People and assets in 2025

Vehicles and equipment

€ 47,340

▼ 21% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 2,490

▲ 4% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 204

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 35,526

▲ 20% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 130,104 Gross margin 2022: € 130,104 First fiscal year in the series	€ 205,871 Gross margin 2023: € 205,871 ▲ 58% vs 2022 (€ 130,104) Favourable step	€ 264,363 Gross margin 2024: € 264,363 ▲ 28% vs 2023 (€ 205,871) Favourable step	€ 353,909 Gross margin 2025: € 353,909 ▲ 34% vs 2024 (€ 264,363) Favourable step	▲ 34%
Profit after taxes	€ 61,796 Profit after taxes 2022: € 61,796 First fiscal year in the series	€ 140,144 Profit after taxes 2023: € 140,144 ▲ 127% vs 2022 (€ 61,796) Favourable step	€ 169,454 Profit after taxes 2024: € 169,454 ▲ 21% vs 2023 (€ 140,144) Favourable step	€ 243,328 Profit after taxes 2025: € 243,328 ▲ 44% vs 2024 (€ 169,454) Favourable step	▲ 44%
Equity	€ 619,167 Equity 2022: € 619,167 First fiscal year in the series	€ 554,311 Equity 2023: € 554,311 ▼ 10% vs 2022 (€ 619,167) Unfavourable step	€ 723,765 Equity 2024: € 723,765 ▲ 31% vs 2023 (€ 554,311) Favourable step	€ 967,093 Equity 2025: € 967,093 ▲ 34% vs 2024 (€ 723,765) Favourable step	▲ 34%
Total debts	€ 16,482 Total debts 2022: € 16,482 First fiscal year in the series	€ 244,029 Total debts 2023: € 244,029 ▲ € 227,548 vs 2022 (€ 16,482) Unfavourable step	€ 45,068 Total debts 2024: € 45,068 ▼ 82% vs 2023 (€ 244,029) Favourable step	€ 50,538 Total debts 2025: € 50,538 ▲ 12% vs 2024 (€ 45,068) Unfavourable step	▲ 12%
Cash	€ 214,815 Cash 2022: € 214,815 First fiscal year in the series	€ 317,676 Cash 2023: € 317,676 ▲ 48% vs 2022 (€ 214,815) Favourable step	€ 71,959 Cash 2024: € 71,959 ▼ 77% vs 2023 (€ 317,676) Unfavourable step	€ 347,139 Cash 2025: € 347,139 ▲ € 275,180 vs 2024 (€ 71,959) Favourable step	▲ € 275,180
Land & buildings	€ 188,477 Land & buildings 2022: € 188,477 First fiscal year in the series	€ 168,938 Land & buildings 2023: € 168,938 ▼ 10% vs 2022 (€ 188,477) Unchanged	€ 149,399 Land & buildings 2024: € 149,399 ▼ 12% vs 2023 (€ 168,938) Unchanged	€ 129,860 Land & buildings 2025: € 129,860 ▼ 13% vs 2024 (€ 149,399) Unchanged	▼ 13%
Retained profit	€ 606,775 Retained profit 2022: € 606,775 First fiscal year in the series	€ 541,919 Retained profit 2023: € 541,919 ▼ 11% vs 2022 (€ 606,775) Unfavourable step	€ 711,372 Retained profit 2024: € 711,372 ▲ 31% vs 2023 (€ 541,919) Favourable step	€ 954,701 Retained profit 2025: € 954,701 ▲ 34% vs 2024 (€ 711,372) Favourable step	▲ 34%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 205,000 Dividend 2023: € 205,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 205,000) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 2,260 Bank debt 2023: € 2,260 Unchanged (€ 0) Unfavourable step	€ 2,390 Bank debt 2024: € 2,390 ▲ 6% vs 2023 (€ 2,260) Unfavourable step	€ 2,490 Bank debt 2025: € 2,490 ▲ 4% vs 2024 (€ 2,390) Unfavourable step	▲ 4%
Balance sheet total	€ 635,649 Balance sheet total 2022: € 635,649 First fiscal year in the series	€ 798,340 Balance sheet total 2023: € 798,340 ▲ 26% vs 2022 (€ 635,649) Unchanged	€ 768,833 Balance sheet total 2024: € 768,833 ▼ 4% vs 2023 (€ 798,340) Unchanged	€ 1,017,631 Balance sheet total 2025: € 1,017,631 ▲ 32% vs 2024 (€ 768,833) Unchanged	▲ 32%

Key figures of APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE?

What happened at APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jan 30, 2026 New annual accounts for financial year 2025: profit of € 243,328 (▲ 44% vs 2024). Source: NBB ↗
Oct 3, 1995 New establishment in Herent. KBO
1995 Christiaan Julien Vanhentenrijk became a director. NBB
Jul 6, 1995 Start of the company according to the CBE. KBO

In short

From € 61,796 profit in 2022 to € 243,328 profit in 2025.

Paid € 261,286 in corporate taxes since 2022.

Best year ever: 2025, with € 243,328 profit.

Paid out € 205,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Christiaan Julien Vanhentenrijk

APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE

Behind APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE is Christiaan Julien Vanhentenrijk.

Directors

According to the 2025 annual accounts

Christiaan Julien Vanhentenrijk

Director

since 1995

Establishments

Establishment units

Physical locations of this company

Registered office

Ganzemansberg 18

3020 Herent

2.073.274.733

Hoogveldstraat 49

3020 Herent

Active since 3 October 1995

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0455.664.923
VAT number: BE 0455.664.923
Registered office: Ganzemansberg 18, 3020 Herent
Names & denominations: APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 6 July 1995
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗

APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE

Warning lights

Financials

What happened to APOTHEKER CHRIS VANHENTENRIJK, KLINISCHE BIOLOGIE?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions